‏إظهار الرسائل ذات التسميات FDA. إظهار كافة الرسائل
‏إظهار الرسائل ذات التسميات FDA. إظهار كافة الرسائل

Blinkit Faces Maharashtra FDA Action as 18,405 Expired Food Items Are Detected

Blinkit Faces Maharashtra FDA Action as 18,405 Expired Food Items Are Detected

The Maharashtra Food and Drug Administration (FDA) has suspended the food business licence of Blinkit’s Bhiwandi facility after inspectors allegedly found major lapses in the handling and disposal of expired, damaged and rejected food products. The action follows an inspection that uncovered 18,405 food items worth more than ₹32.71 lakh for which the company could not provide adequate traceability records or proof of destruction.

What Triggered the FDA Action?

According to Maharashtra FDA officials, an inspection conducted on 21 October at Blinkit's warehouse facility in Bhiwandi, Maharashtra, revealed that the company was unable to provide end-to-end traceability and documentation showing the disposal of approximately 18,405 expired, damaged or rejected food products valued at more than ₹32.71 lakh.

Regulators stated that the absence of proper records raised concerns about whether the inventory had been safely destroyed as required under food safety regulations. As a result, the FDA ordered the immediate suspension of licensed food operations at the premises.

Public Health Concerns at the Centre

The FDA said its primary concern was the possibility that food items classified as unsaleable could potentially re-enter the consumer market. Officials argued that expired or damaged products pose a direct risk to public health if they are diverted back into commercial channels instead of being scientifically destroyed.

The regulator described the situation as a serious compliance failure because businesses handling food products are required to maintain complete records regarding the storage, movement and destruction of non-saleable inventory.

FIR Filed Against Executives and Vendors

The matter has gone beyond regulatory action and entered the criminal investigation stage.

Following the licence suspension, the Maharashtra FDA registered an FIR at Bhiwandi Taluka Police Station against key Blinkit personnel, including a whole-time director, facility managers and several scrap-disposal vendors.

The accused have reportedly been booked under provisions of the Bharatiya Nyaya Sanhita (BNS), 2023, including sections related to cheating and criminal conspiracy, along with Section 59(i) of the Food Safety and Standards Act, 2006. Authorities have alleged a conspiracy involving the possible resale of expired food products for financial gain. These allegations remain under investigation, and the filing of an FIR does not establish guilt.

Why Bhiwandi Matters

The development is significant because Bhiwandi is one of India's largest warehousing and logistics hubs, serving e-commerce companies, retailers and quick-commerce platforms. The region houses large fulfilment centres that support rapid delivery operations across Mumbai and neighbouring markets.

Any disruption in operations at a major warehouse can have implications for inventory management and supply-chain processes, particularly in the fast-growing quick-commerce industry where speed and inventory turnover are critical.

Part of a Wider FDA Crackdown

The action against Blinkit appears to be part of a broader enforcement drive by the Maharashtra FDA under Food and Drug Administration Commissioner Tukaram Mundhe. The regulator has recently intensified inspections of warehouses, dark stores and waste-disposal networks amid concerns that expired or rejected food products may be finding their way back into retail channels.

Authorities have conducted multiple raids targeting suspected diversion networks and have reportedly booked several individuals connected to food companies, disposal agencies and local traders in related investigations.

A Fresh Setback for Blinkit

The latest suspension comes just months after another FDA action involving a Blinkit facility in Mumbai's Malad area, where inspectors reported hygiene and food-safety violations, including the presence of expired products and poor storage conditions.

While the Bhiwandi case centres on inventory traceability and disposal records rather than hygiene issues, both incidents underscore increasing regulatory scrutiny of quick-commerce operators that handle large volumes of food products.

Industry-Wide Implications

The Maharashtra FDA's action signals a tougher regulatory stance toward food inventory management across the e-commerce and quick-commerce ecosystem. The case highlights the growing importance of:
  • Maintaining complete traceability of food products.
  • Proper destruction of expired and damaged inventory.
  • Robust record-keeping and compliance systems.
  • Preventing unsaleable food stock from re-entering the market.
  • Strengthening oversight of third-party disposal vendors.
As investigations continue, regulators are expected to closely monitor how food businesses manage expired inventory and comply with food safety norms.

Conclusion

The suspension of Blinkit's Bhiwandi food licence marks one of the most significant enforcement actions taken by the Maharashtra FDA against a quick-commerce operator in recent months. With 18,405 food items worth ₹32.71 lakh at the centre of the case, and an FIR now lodged against company personnel and vendors, the investigation could become a defining test of inventory traceability and food-safety compliance standards within India's rapidly expanding quick-commerce sector.

In a First of Its Kind, Samsung Galaxy's Feature Which Detects Signs of Sleep Apnea Gets US FDA Authorization

In a First of Its Kind, Samsung Galaxy's Feature Which Detects Signs of Sleep Apnea Gets US FDA Authorization

Samsung Electronics announced that the sleep apnea feature¹ on the Samsung Health Monitor app² has received De Novo authorization from the U.S. Food and Drug Administration (FDA). This feature, which detects signs of sleep apnea using a compatible Samsung Galaxy Watch and phone, was the first of its kind to be authorized by the FDA following previous approval by Korea’s Ministry of Food and Drug Safety (MFDS), announced last October in Korea.

The sleep apnea feature enables users over the age of 22 who have not been diagnosed with sleep apnea to detect signs of moderate to severe obstructive sleep apnea (OSA) over a two-night monitoring period, a common and chronic sleep condition that often goes undiagnosed and untreated. To utilize the feature, users can simply track their sleep twice for more than four hours within a ten-day period.

In a First of Its Kind, Samsung Galaxy's Feature Which Detects Signs of Sleep Apnea Gets US FDA Authorization

OSA causes a person to stop breathing while sleeping and can often result in disruptions in oxygen supply, decreased sleep quality and increased daytime fatigue. Untreated sleep apnea can compound the risk of cardiovascular diseases such as hypertension, coronary artery disease, heart failure, cardiac arrhythmia and stroke. According to the National Sleep Foundation (NSF), roughly 25% of men and 10% of women in the U.S. experience OSA. The new feature on the Samsung Health Monitor app is expected to help more people proactively detect moderate or severe forms of OSA, and as a result of the detection seek medical care to reduce the possibility of health-related complications.

Good health is strongly linked to good sleep. Sleep helps bodies and minds recover and empowers people to wake up refreshed and ready for the day ahead. The quality of sleep people get every night has a significant impact on their physical and mental well-being, relationships, performance and more. Samsung recognizes the foundational role that sleep serves in people’s health and well-being by focusing on three key elements for better sleep: understanding sleep patterns, building better habits and creating a sleep-friendly environment.

With the sleep apnea feature, Samsung is taking the next step in its ongoing commitment to provide Galaxy users with the best possible sleep tools to improve their sleep health habits. The feature will be available on the Galaxy Watch series in the U.S. via the Samsung Health Monitor app in the third quarter.³

1 The Sleep Apnea Feature is an over-the-counter (OTC) software-only, mobile medical application operating on a compatible Samsung Galaxy Watch and phone. This feature is intended to detect signs of moderate to severe obstructive sleep apnea in the form of significant breathing disruptions in adult users 22 years and older, over a two-night monitoring period. It is intended for on-demand use. This feature is not intended for users who have previously been diagnosed with sleep apnea. Users should not use this feature to replace traditional methods of diagnosis and treatment by a qualified clinician. The data provided by this device is also not intended to assist clinicians in diagnosing sleep disorders.
2 Availability may vary by market or device. Due to market restrictions in obtaining approval/registration as a Software as a Medical Device (SaMD), it only works on watches and phones purchased in the markets where service is currently available (however, service may be restricted when users travel to non-service markets).
3 Availability may vary by market, carrier, model, or paired phone.

For Its Blood Test to Detect Early-stage Prostate Cancer, Mumbai-based Datar Cancer Genetics Gets 'Breakthrough Designation' from the US FDA

Representational Image

The US FDA grants the coveted Breakthrough Designation for Early-Stage Prostate Cancer Detection Blood Test Developed in India by Datar Cancer Genetics

It is the first blood test able to detect early-stage Prostate Cancer with high accuracy in men aged 55 years and above

Datar Cancer Genetics today announced that the US Food and Drug Administration (FDA) has granted 'Breakthrough Designation' for its blood test to detect early-stage prostate cancer. This is the second test from Datar Cancer Genetics that has received the Breakthrough Device Designation from the US FDA. Late last year, Datar Cancer Genetics’ breast cancer detection test became the first such test to receive the designation.

This is the first blood test for men which can detect early-stage prostate cancer with high accuracy. The test is available in India by the name of Easycheck. Men with serum PSA of more than 3 ng / mL can avail of this test in consultation with their physician. The test requires 5 ml blood and does not involve exposure to radiation or any of the discomforts of a digital rectal examination. 

The blood test is based on the detection of Circulating Tumor Cells (CTCs) specific to prostate adenocarcinoma. The test can detect early-stage prostate cancers with more than 99% accuracy without any false positives. The test has been validated in large clinical studies involving healthy males and prostate cancer patients.

In India, about 35,000 men were detected with prostate cancer in 2020 and this number is slated to increase every year, as is the case for all cancers due to various risk factors. Unfortunately, most prostate cancer cases are detected at late stages (III or IV) where it has spread to other organs. In such cases, curative surgeries that can remove the cancerous tissue are not viable options, and treatment involves long-term administration of anticancer drugs to manage the disease. If detected at early stages where cancer has not spread out of the prostate, prostate cancer has a very high (>99%) chance of being cured.

"About 75% of prostate biopsies are benign and with foreknowledge, these could be potentially avoided. The new blood test by the Datar team will help Doctors decide precisely the patients who need a biopsy and who do not. This is a very significant scientific advancement in the complex field of liquid biopsies coming from India. I congratulate the Datar team for their exemplary work and achievement," said Dr. Sewanti Limaye, Director of Medical and Precision Oncology and Oncology Research, Sir HN Reliance Foundation Hospital and Research Centre, Mumbai.

"It is a landmark acknowledgement that the US FDA has recognized the potential benefits of our 'first in the world' prostate cancer detection test. The highly coveted 'Breakthrough Designation' is granted after very rigorous evaluation. We take great pride in the fact that this test has been wholly developed in India and by Indian scientists and clinicians. This is our ongoing contribution to the Prime Minister's 'Atmanirbhar Bharat' mission after the breakthrough breast cancer detection test and is further intended to augment the global fight against cancer," said Mr. Rajan Datar, Chairman of the Company.

Appreciably, getting the test does not involve having to go to any hospital or health centre and waiting for appointments. The blood collection for this test can be done in the convenience and privacy of one's home or office after which the patient can go about their routine work. From the patient's point of view, the whole process is very non-intrusive.

The test is already available in Europe and is CE marked. The Company is in discussions with several leading healthcare providers for ready accessibility in India.

About Datar Cancer Genetics

Datar Cancer Genetics is a global oncology research and applications company that is spearheading the development of non-invasive technologies for improved detection, treatment and management of cancer. The Company's state-of-the-art cancer research centre is NABL, ISO, CAP and CLIA accredited. The Company serves cancer patients and suspected cases in the UK, European Union, United States, GCC, and India.

Market Reports

Market Report & Surveys
IndianWeb2.com © all rights reserved